Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + cetuximab + irinotecan versus investigator's choice third-line therapy in previously treated RAS wild-type metastatic colorectal cancer
ChiCTR2200061365Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab, cetuximab and irinotecan in colorectal cancer (CRC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: progression-free survival. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
tislelizumabcetuximabirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2200061365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061365.